Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

SMS Pharmaceuticals gets EIR for Bachupally facility

The company's manufacturing facility at Bachupally, Hyderabad, has received EIR from the United States Food and Drug Administration (USFDA), SMS Pharmaceuticals said in a filing to the BSE.

January 22, 2018 / 03:42 PM IST
Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm SMS Pharmaceuticals today said it has received establishment inspection report (EIR) from the US health regulator for its Bachupally facility in Hyderabad.

The company's manufacturing facility at Bachupally, Hyderabad, has received EIR from the United States Food and Drug Administration (USFDA), SMS Pharmaceuticals said in a filing to the BSE.

"The facility was inspected by the USFDA in November 2017 and there were no Form 483 observations during the inspection," it added.

As per the USFDA, an EIR is issued to a company after the completion of an inspection of its facility detailing inspectional findings.

Shares of SMS Pharmaceuticals were today trading at Rs 105.45 apiece in afternoon trade on the BSE, up 3.79 per cent from their previous close.

PTI
first published: Jan 22, 2018 03:37 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347